Filing Details

Accession Number:
0000899243-22-008821
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-03-02 21:08:05
Reporting Period:
2022-02-28
Accepted Time:
2022-03-02 21:08:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1521036 Lantheus Holdings Inc. LNTH In Vitro & In Vivo Diagnostic Substances (2835) 352318913
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1861400 Carol Walker C/O Lantheus Holdings, Inc.
331 Treble Cove Road
North Billerica MA 01862
Senior Vice President, Quality No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-02-28 6,181 $0.00 82,550 No 4 A Direct
Common Stock Disposition 2022-03-01 6,956 $48.04 75,594 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. The transaction reported in this Form 4 reflects additional shares of common stock issued by the Company to the reporting person upon the vesting of relative Total Shareholder Return performance-based restricted stock units ("PSUs") that were previously granted and included in the Form 3 filed upon the reporting person becoming a Section 16 officer. The number of shares reported in the Form 3 reflected 100% of the target number of shares underlying the PSUs. The number of shares that actually vested under the PSUs equaled 188% of the target number of shares. Accordingly, the number of shares reported in this Form 4 reflects the difference between the number of shares that actually vested under the PSUs and the target number of shares originally included in the Form 3.
  2. Includes 166 shares acquired under the LNTH employee stock purchase plan on September 23, 2021.
  3. The Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions in compliance with Rule 10b5-1. The transaction reported in this Form 4 was effected in compliance with Rule 10b5-1 to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4.